Visterra Overview
- Founded
- 2007
- Status
- Acquired/Merged
- Employees
- 42
- Latest Deal Type
- M&A
- Latest Deal Amount
- $430M
Visterra General Information
Description
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company's novel platform designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed, enabling the patients to seek the significant unmet need for effective therapies.
Contact Information
Website
www.visterrainc.com
Formerly Known As
Parasol Therapeutics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 275 2nd Avenue
- Waltham, MA 02451
- United States
+1 (617) 000-0000
Visterra Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 31-Aug-2018 | $430M | 00000 | 00000 | Completed | Generating Revenue |
| 8. Later Stage VC (Series C) | 05-Oct-2017 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 7. IPO | 10-Feb-2017 | 0000 | 00000 | Cancelled | Generating Revenue | |
| 6. Grant | 29-Sep-2015 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 5. Later Stage VC (Series B) | 15-May-2014 | 0000 | 000.00 | 00000 | Completed | Pre-Clinical Trials |
| 4. Later Stage VC (Series A) | 02-Dec-2013 | 000.00 | 000.00 | 0000 | Completed | Startup |
| 3. Debt - General | 17-Sep-2010 | 000 | 000.00 | Completed | Startup | |
| 2. Seed Round | 07-Dec-2009 | $3.6M | $5.64M | 00.00 | Completed | Startup |
| 1. Seed Round | 28-Jan-2008 | $2.04M | $2.04M | 00.000 | Completed | Startup |
Visterra Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 000 | |
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series A | 32,447,072 | $0.000100 | $1 | $1 | 1x | $1 | 28.51% | |
| Seed | 6,178,926 | $0.000100 | $1 | $1 | 1x | $1 | 5.43% |
Visterra Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The co
Biotechnology
Waltham, MA
42
As of 2018
00000
0000
0000-00-00
000000&0
00000
00000000
quip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000 000000000
Vienna, Austria
00.000
00000000000
00.000
00000000
onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
Rockville, MD
0
As of 0000
000.00
0000000000 0
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialVisterra Competitors (86)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apeptico | Venture Capital-Backed | Vienna, Austria | 00.000 | 00000000000 | 00.000 | |
| 000000000 00000000 | Venture Capital-Backed | Rockville, MD | 0 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 0000000000 | 000.00 |
| 00 00000000 | Venture Capital-Backed | Glasgow, United Kingdom | 00 | 000.00 | 00000000 | 000.00 |
Visterra Patents
Visterra Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210316004-A1 | Antibody molecule-drug conjugates and uses thereof | Pending | 03-Apr-2020 | 00000000000 | |
| US-20210024601-A1 | Interleukin-2 agents and uses thereof | Pending | 26-Jul-2019 | 000000000 | |
| US-20200392241-A1 | Humanized antibody molecules to cd138 and uses thereof | Pending | 17-Jun-2019 | 00000000000 | |
| US-20200308257-A1 | Compositions and methods for treating and preventing influenza | Pending | 25-Mar-2019 | 00000000000 | |
| CA-3132521-A1 | Compositions and methods for treating and preventing influenza | Pending | 25-Mar-2019 | C07K16/1018 |
Visterra Executive Team (15)
Visterra Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brian Pereira MD | Visterra | President, Chief Executive Officer and Board Member | 000 0000 |
| Ram Sasisekharan Ph.D | Visterra | Co-Founder, Scientific Founder and Board Member | 000 0000 |
Visterra Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialVisterra Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Allegheny Financial Group | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
| CTI Life Sciences Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Cycad Group | Venture Capital | Minority | 000 0000 | 000000 0 |
